Nephoxil can be prescribed at general hospitals

a treatment for hyperphosphatemia

Landing at 50 medical institutions nationwide, including Severance

Nephoxil, a hyperphosphatemia treatment drug, is entering the prescription range of general hospitals.

 

According to related industries, Kyowa Kirin Korea's Nepocsil has passed the Drug Committee of about 50 hospitals across the country, including Sinchon Severance Hospital.

 

Nephoxil was developed as a new iron-based phosphorus binder with high solubility, and through clinical trials, it not only has a phosphorus control effect but also has an additional anemia correction effect, reducing the dosage of hematopoietic hormones and iron injections.

 

In addition, the capsule formulation is evaluated to not only improve medication compliance but also contribute to the economical treatment of hyperphosphatemia patients among hemodialysis patients.

 

Nephoxil was approved for improving hyperphosphatemia in chronic kidney disease patients receiving hemodialysis and was listed on the health insurance coverage list on July 1.

 

It is imported and sold by Kyowa Kirin Korea, the Korean subsidiary of Japanese Kyowa Kirin, but it was developed by a Taiwanese pharmaceutical company, not Japan.

 

This can be seen as a rare case where a Taiwanese new drug was imported domestically and even applied for reimbursement.

 

In particular, this drug was not listed in the A7 reference country, but it was cheaper than alternative drugs and took only 1 year and 2 months from approval to reimbursement.

 

Non-calcium drugs currently on the market include Sanofi Renvela, SK Chemicals Invela, and JW Pharmaceuticals Fosrenol.

 

In particular, several generic Renvela drugs have recently come out and are competing with it.